A retrospective longitudinal study of 52 Finnish patients with X‐linked retinoschisis
Acta Ophthalmologica · 2025
DOI: 10.1111/aos.16776 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Ophthalmologica, 2025. Verfasst von Mira A Järvinen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. Hauptthemen laut MEDLINE: Retinoschisis, Visual Acuity, Eye Proteins, Retina. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Samfundet Folkhälsan, Silmä- ja kudospankkisäätiö, Silmäsäätiö.
Abstract (Originalsprache)
Purpose
To describe clinical characteristics in Finnish patients with X‐linked retinoschisis (XLRS) longitudinally with emphasis on retinal morphology and genotype–phenotype correlations.
Methods
A retrospective cohort study reviewed medical records from patients with genetically confirmed XLRS from the Department of Ophthalmology, Helsinki University Hospital. Best‐corrected visual acuity (BCVA), refraction, colour fundus photography, spectral‐domain optical coherence tomography and genetic information were collected.
Results
Fifty‐two males were diagnosed at the median age of 7 years (range 1–57) and followed for a median of 8 years (range, 1–49). Baseline findings included macular retinoschisis in 92 (89%), macular atrophy in 25 (24%) and peripheral retinoschisis in 22 (21%) eyes. Vitreous haemorrhage occurred in 10 (10%) eyes, more frequently with peripheral schisis ( p < 0.001). Nearly half of the patients, 22 (42%) were classified as visually impaired according to WHO. Median central retinal thickness was similar between initial (355 μm) and latest visits (360 μm) ( p = 0.781). Low BCVA was associated with macular atrophy ( p < 0.001), ellipsoid zone disruption ( p = 0.007) and peripheral retinoschisis ( p = 0.006). The three Finnish founder mutations c.214G >A, c.221G >T, and c.325G >C in exon 4 of retinoschisin 1 ( RS1 ) were identified in 40 patients (77%). No associations were found between the genotypes and phenotypes.
Conclusion
Three‐fourths of the patients carried the Finnish founder mutations in RS1 , but we did not detect any genotype–phenotype association. Macular atrophy was associated with the poorest visual acuity. Ocular compilations were associated with peripheral retinoschisis, suggesting that these patients should be followed more frequently.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
- National Centre for Optics, Vision and Eye Care, Faculty of Health and Social Sciences, University of South-Eastern Norway, Kongsberg, Norway.
- Eye Genetics Group, Folkhälsan Research Center, Biomedicum Helsinki, Helsinki, Finland.
ORCID-Profile: Rigmor C Baraas, Anna Majander, Tero T Kivelä, Joni A Turunen
Förderung
- Samfundet Folkhälsan
- Silmä- ja kudospankkisäätiö
- Silmäsäätiö
Zitieren
APA
Järvinen, M. A., Baraas, R. C., Majander, A., Backlund, M. P., Krootila, J., Paavo, M., Lindahl, P., Vasara, K., Sankila, E. M., Kivelä, T. T., & Turunen, J. A. (2025). A retrospective longitudinal study of 52 Finnish patients with X‐linked retinoschisis. Acta Ophthalmologica. https://doi.org/10.1111/aos.16776
Vancouver
Järvinen MA, Baraas RC, Majander A, Backlund MP, Krootila J, Paavo M, et al. A retrospective longitudinal study of 52 Finnish patients with X‐linked retinoschisis. Acta Ophthalmologica. 2025. doi:10.1111/aos.16776
BibTeX
@article{Jrvinen2025,
author = {Järvinen, Mira A and Baraas, Rigmor C and Majander, Anna and Backlund, Michael P and Krootila, Julia and Paavo, Maarjaliis and Lindahl, Päivi and Vasara, Kristiina and Sankila, Eeva-Marja and Kivelä, Tero T and Turunen, Joni A},
title = {A retrospective longitudinal study of 52 Finnish patients with X‐linked retinoschisis},
journal = {Acta Ophthalmologica},
year = {2025},
doi = {10.1111/aos.16776}
}
EUVIMED